| Drug Name |
Apomorphine hydrochloride |
| Drug ID |
BADD_D00153 |
| Description |
Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618]
Apomorphine was granted FDA approval on 20 April 2004.[L13919] |
| Indications and Usage |
For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
G04BE07; N04BC07 |
| DrugBank ID |
DB00714
|
| KEGG ID |
D02004
|
| MeSH ID |
D001058
|
| PubChem ID |
9410
|
| TTD Drug ID |
D0H6QU
|
| NDC Product Code |
63402-015; 63402-120; 63402-115; 63402-010; 63402-188; 63402-020; 63402-130; 49452-0700; 38779-1764; 52817-720; 63402-125; 63402-088; 27505-004; 62991-1513; 52465-104; 52465-105; 63402-030; 63402-025; 12707-031; 51927-2303; 50396-6009; 63402-110 |
| Synonyms |
Apomorphine | Apomorphine Hydrochloride, Anhydrous | Apomorphine Hydrochloride Anhydrous | Apomorphine Hydrochloride | Apomorphin-Teclapharm | Apomorphin Teclapharm | Apomorphine Hydrochloride, Hemihydrate | Apokinon | Apomorphine Chloride | Britaject |
